Literature DB >> 31586260

Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.

Marzia Anita Lucia Romeo1, Marina Chiara Garassino2, Lucia Moiola1, Giulia Galli2, Giancarlo Comi3, Vittorio Martinelli1, Massimo Filippi4,5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31586260     DOI： 10.1007/s00415-019-09562-z

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  9 in total

1.  Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.

Authors:  Irene Cortese; Pawel Muranski; Yoshimi Enose-Akahata; Seung-Kwon Ha; Bryan Smith; MariaChiara Monaco; Caroline Ryschkewitsch; Eugene O Major; Joan Ohayon; Matthew K Schindler; Erin Beck; Lauren B Reoma; Steve Jacobson; Daniel S Reich; Avindra Nath
Journal:  N Engl J Med       Date:  2019-04-10       Impact factor: 91.245

2.  Role of the Programmed Death-1 (PD-1) pathway in regulation of Theiler's murine encephalomyelitis virus-induced demyelinating disease.

Authors:  Sho Takizawa; Tomoki Kaneyama; Sayaka Tsugane; Naoya Takeichi; Satoshi Yanagisawa; Motoki Ichikawa; Hideo Yagita; Byung S Kim; Chang-Sung Koh
Journal:  J Neuroimmunol       Date:  2014-06-27       Impact factor: 3.478

Review 3.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Authors:  Alan J Thompson; Brenda L Banwell; Frederik Barkhof; William M Carroll; Timothy Coetzee; Giancarlo Comi; Jorge Correale; Franz Fazekas; Massimo Filippi; Mark S Freedman; Kazuo Fujihara; Steven L Galetta; Hans Peter Hartung; Ludwig Kappos; Fred D Lublin; Ruth Ann Marrie; Aaron E Miller; David H Miller; Xavier Montalban; Ellen M Mowry; Per Soelberg Sorensen; Mar Tintoré; Anthony L Traboulsee; Maria Trojano; Bernard M J Uitdehaag; Sandra Vukusic; Emmanuelle Waubant; Brian G Weinshenker; Stephen C Reingold; Jeffrey A Cohen
Journal:  Lancet Neurol       Date:  2017-12-21       Impact factor: 44.182

Review 4.  Multiple sclerosis outcomes after cancer immunotherapy.

Authors:  Catherine R Garcia; Rani Jayswal; Val Adams; Lowell B Anthony; John L Villano
Journal:  Clin Transl Oncol       Date:  2019-02-20       Impact factor: 3.405

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

7.  Neurologic complications of immune checkpoint inhibitors.

Authors:  Avi Fellner; Chen Makranz; Michal Lotem; Felix Bokstein; Alisa Taliansky; Shai Rosenberg; Deborah T Blumenthal; Jacob Mandel; Suzana Fichman; Elena Kogan; Israel Steiner; Tali Siegal; Alexander Lossos; Shlomit Yust-Katz
Journal:  J Neurooncol       Date:  2018-01-13       Impact factor: 4.130

8.  Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease.

Authors:  Daria Trabattoni; Marina Saresella; Michela Pacei; Ivana Marventano; Laura Mendozzi; Marco Rovaris; Domenico Caputo; Manuela Borelli; Mario Clerici
Journal:  J Immunol       Date:  2009-09-30       Impact factor: 5.422

Review 9.  Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.

Authors:  Shrujal Baxi; Annie Yang; Renee L Gennarelli; Niloufer Khan; Ziwei Wang; Lindsay Boyce; Deborah Korenstein
Journal:  BMJ       Date:  2018-03-14
  9 in total
  1 in total

Review 1.  Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature.

Authors:  Marcos C B Oliveira; Marcelo H de Brito; Mateus M Simabukuro
Journal:  Front Neurol       Date:  2020-12-11       Impact factor: 4.003
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.